Presence and functions of immune components in the tumor microenvironment

Advances in Experimental Medicine and Biology

Volumn 495, Issue , 2001, Pages 317-324

  Witz, Isaac P ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

CONFERENCE PAPER; HUMAN; LYMPHOCYTE FUNCTION; MACROPHAGE; MACROPHAGE FUNCTION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

EID: 0035699825     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0685-0_44     Document Type: Conference Paper

References (54)

1. Genetic instabilities in human cancers
2. Oncogene amplification in solid tumors
3. Tumor suppressor genes
4. Expression genetics in cancer: Shifting the focus from DNA to RNA
5. Cytokines in tumour growth, migration and metastasis
6. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
7. The significance of matrix metalloproteinases during early stages of tumor progression
8. Fibronectin and its integrin receptors in cancer
9. Establishing a link between oncogenes and tumor angiogenesis
10. Differential expression of genes by tumor cells of a low or a high malignancy phenotype: The case of murine and human Ly-6 proteins
11. Critical determinants of cancer metastasis: Rationale for therapy
12. Mutagenesis induced by the tumor microenvironment
13. The role of CD4+ tumor-infiltrating lymphocytes in human solid tumors
14. Cytokine regulation of monocyte recruitment
15. Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression
16. A review of data, problems, and open questions pertaining to in situ tumor immunity
17. Separation and characteristics of tumor-infiltrating lymphocytes in man
18. Correlations between tumor antigenicity, malignant potential, and local host immune response
19. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors
20. Cancer vaccines based on the identification of genes encoding cancer regression antigens
21. Human tumor antigens for cancer vaccine development
22. Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma
23. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma
24. Signaling defects in T lymphocytes of patients with malignancy
25. Expression of Fas and Fas ligand and apoptosis in tumor-associated lymphocytes and in tumor cells from malignant pleural effusions
26. Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma
27. Adoptive cellular therapy
28. Cell therapy: Achievements and perspectives
29. Physiologically based kinetic model of effector cell biodistribution in mammals: Implications for adoptive immunotherapy
30. Structure of the gene of tum-transplantation antigen P198: A point mutation generates a new antigenic peptide
31. Tumor antigens recognized by T cells
32. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome-encapsulated immunomodulators
33. The origin and function of tumor-associated macrophages
34. Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines
35. Cytokine regulation of angiogenesis in breast cancer: The role of tumor-associated macrophages
36. Critical evaluation of bispecific antibodies as targeting agents for boron neutron capture therapy of brain tumors
37. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
38. Monoclonal antibody therapy of cancer
39. Antibodies in the therapy of colon cancer
40. Recombinant antibody fragment and immunotoxin fusions for cancer therapy
41. Monoclonal antibody therapy for solid tumors
42. Tumor-bound immunoglobulins: In situ expression of humoral immunity
43. Lymphocytotoxic auto antibodies eluted from in-vivo propagating sarcoma cells
44. The in-vivo acquisition of Fc gamma RII expression on polyomas virus transformed cells derived from tumors of long latency
45. FcR may function as a progression factor of non-lymphoid tumors
46. The contribution of the intracellular domain of the murine Fc-gamma receptor type I1 B1 to its tumor enhancing potential
47. Regulation of tumor growth and immunomodulation mediated by naturally-occurring autoantibodies
48. Cytokines and Cancer
49. Analysis of Th 1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients
50. Targeted cytokines for cancer immunotherapy
51. Cytokine therapy for cancer
52. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity
53. TNF promotes metastasis by impairing natural killer cell activity
54. The role of transforming growth factor-beta (TGF-beta) in human cancer